
    
      This study is divided into two parts.

      The first part is a multiple dose pharmacokinetic and pharmacodynamics study of Apixaban in
      patient with stable renal function. The primary purpose of this study is to provide a clear
      understanding of the effect of creatinine clearance on pharmacokinetics and pharmacodynamics
      of Apixaban among Thai patients with nonvalvular atrial fibrillation. To assess the
      pharmacokinetics and pharmacodynamics of Apixaban, This study will enroll 30 subjects who
      meet the inclusion criteria.

      The second part of this study will retrospectively determine the occurrent of clinical
      outcome between patients who were prescribed apixaban dose concordant and discordant to the
      drug leaflet. A total of 241 subjects will be recruited. The follow up period will begin from
      the time of initiation of apixaban until occurrent of stoke, transient ischemic attack,
      systemic embolism, bleeding, or death.
    
  